Impfungen bei Kindern und Jugendlichen mit onkologischer Grunderkrankung

Eine onkologische Therapie führt zu einer Immundefizienz und somit zum Verlust der zellulären und humoralen Immunität. So geht auch die vormals durch Impfungen erworbene Immunität gegen entsprechende Infektionskrankheiten verloren. Wann der optimale Zeitpunkt für Wiederholungsimpfungen ist und welche Impfungen erneut vorzunehmen sind, wurde durch eine aktuelle Stellungnahme der Ständigen Impfkommission (STIKO) bearbeitet und publiziert.

Schlüsselwörter

Pädiatrie - Onkologie - Kinder - Krebserkrankung - Leukämie - Tumorerkrankung - Impfung - SARS-CoV-2 - Chemotherapie

• Literatur

• 1 Smith PG. Concepts of herd protection and immunity. Procedia in Vaccinology 2010; 2: 134-139
• 2 Kaatsch P GD, Spix C. German Childhood Cancer Registry – Annual Report 2018 (1980 – 2017). In: Deutsches Kinderkrebsregister. Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI) at the University Medical Center of the Johannes Gutenberg University Mainz; 2019
• 3 Crawford NW, Heath JA, Ashley D. et al. Survivors of childhood cancer: an Australian audit of vaccination status after treatment. Pediatr Blood Cancer 2010; 54 (01) 128-133
• 4 Pagaoa MA, Okcu MF, Bondy ML. Associations between vaccination and childhood cancers in Texas regions. J Pediatr 2011; 158 (06) 996-1002
• 5 Karpocheva SV, Kostinov MP, Zaeva GE. et al. The revaccination against diphtheria and tetanus with adsorbed DT-m anatoxin of children having solid tumors in their case histories. Zh Mikrobiol Epidemiol Immunobiol 1999; 4: 46-49
• 6 Laws H, Baumann U, Bogdan C. et al. Impfen bei Immundefizienz. Bundesgesundheitsbl 2020; 63: 588-644
• 7 Lehrnbecher T, Foster C, Vazquez N. et al. Therapy-induced alterations in host defense in children receiving therapy for cancer. J Pediatr Hematol/Oncol 1997; 19: 399-417
• 8 Perkins JL, Chen Y, Harris A. et al. Infections Among Long-term Survivors of Childhood and Adolescent Cancer: A Report From the Childhood Cancer Survivor Study. Cancer 2014; 120 (16) 2514-2521
• 9 Feldman S, Gigliotti F, Shenep JL. et al. Risk of Haemophilus influenzae type b disease in children with cancer and response of immunocompromised leukemic children to a conjugate vaccine. J Infect Dis 1990; 161 (05) 926-931
• 10 Meisel R, Toschke AM, Heiligensetzer C. et al. Increased risk for invasive pneumococcal diseases in children with acute lymphoblastic leukaemia. Br J Haematol 2007; 137 (05) 457-460
• 11 Van Tilburg CM, Sanders EA, Rovers MM. et al. Loss of antibodies and response to (re-)vaccination in children after treatment for acute lymphocytic leukemia: a systematic review. Leukemia 2006; 20 (10) 1717-1722
• 12 Paulides M, Stohr W, Laws HJ. et al. Antibody levels against tetanus and diphtheria after polychemotherapy for childhood sarcoma: a report from the Late Effects Surveillance System. Vaccine 2011; 29 (08) 1565-1568
• 13 Calaminus G, Hense B, Laws HJ. et al. Diphtheria (D) and tetanus (T) antibody values in children with acute lymphoblastic leukaemia (ALL) after treatment according to Co-ALL05/92. Klin Padiatr 2007; 219 (06) 355-360
• 14 Eyrich M, Wiegering V, Lim A. et al. Immune function in children under chemotherapy for standard risk acute lymphoblastic leukaemia – a prospective study of 20 paediatric patients. Br J Haematol 2009; 147 (03) 360-370
• 15 Mackall CL, Fleisher TA, Brown MR. et al. Distinctions between CD8 + and CD4 + T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood 1997; 89: 3700-3707
• 16 Hakim H, Dallas R, Zhou Y. et al. Acute respiratory infections in children and adolescents with acute lymphoblastic leukemia. Cancer 2016; 122 (05) 798-805
• 17 Goossen GM, Kremer LC, van de Wetering MD. Influenza vaccination in children being treated with chemotherapy for cancer. Cochrane Database Syst Rev 2013; (08) CD006484
• 18 Choi DK, Fuleihan RL, Walterhouse DO. Serologic response and clinical efficacy of influenza vaccination in children and young adults on chemotherapy for cancer. Pediatr Blood Cancer 2016; 63 (11) 2011-2018
• 19 Kotecha RS, Wadia UD, Jacoby P. et al. Immunogenicity and clinical effectiveness of the trivalent inactivated influenza vaccine in immunocompromised children undergoing treatment for cancer. Cancer Med 2016; 5 (02) 285-293
• 20 Mikulska M, Cesaro S, de Lavallade H. et al. Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL7).
• 21 Rubin LG, Levin MJ, Ljungman P. et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58 (03) 309-318
• 22 Cesaro S, Giacchino M, Fioredda F. et al. Guidelines on vaccinations in paediatric haematology and oncology patients. BioMed Res Int 2014; 2014
• 23 Smedegaard LM, Poulsen A, Kristensen IA. et al. Varicella Vaccination of Children With Leukemia Without Interruption of Maintenance Therapy: A Danish Experience. Pediatr Infect Dis J 2016; 35 (11) e348-e352
• 24 Van de Wetering MD, Vossen MT, Jansen MH. et al. Varicella vaccination in pediatric oncology patients without interruption of chemotherapy. J Clin Virol 2016; 75: 47-52
• 25 Schrauder A, Henke-Gendo C, Seidemann K. et al. Varicella vaccination in a child with acute lymphoblastic leukaemia. Lancet 2007; 369(9568): 1232
• 26 Van der Kolk LE, Baars JW, Prins MH. et al. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002; 100 (06) 2257-2259
• 27 Bingham 3rd CO, Looney RJ, Deodhar A. et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheumatism 2010; 62 (01) 64-74
• 28 Niehues T, Bogdan C, Hecht J. Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen (I) Grundlagenpapier. Bundesgesundheitsbl 2017; 60 (06) 674-684
• 29 Ständige Impfkommission. Wissenschaftliche Begründung für die Änderung der Empfehlung zur Impfung gegen Hepatitis B. Epidemiol Bull 2013; 36/37: 371-381
• 30 Ständige Impfkommission. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut. Epidemiol Bull 2018; 34: 335-382
• 31 Ständige Impfkommission. Stellungnahme der STIKO: Fachliche Anwendungshinweise zur Masern-Postexpositionsprophylaxe bei Risikopersonen. Epidemiol Bull 2017; 2: 17-25
• 32 Schiff GM. Titered Lots of Immune Globulin (Ig): Efficacy in the Prevention of Rubella. JAMA Pediatrics 1969; 118: 322-327
• 33 Copelovici Y, Strulovici D, Cristea AL. et al. Data on the efficiency of specific antimumps immunoglobulins in the prevention of mumps and of its complications. Virologie 1979; 30: 171-177
• 34 ACIP. General recommendations on immunization – recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60 (02) 1-64
• 35 Robert Koch-Institut. Fachliche Anwendungshinweise zur Masern-Postexpositionsprophylaxe bei Risikopersonen. Epidemiol Bull 2017; (02) 17-25
• 36 Laws HJ, Simon A, Lehrnbecher T. Revaccination in Children Undergoing Autologous Hematopoietic Stem Cell Transplantation: Results of a Survey in Germany, Austria and Switzerland. Klin Padiatr 2019; 231 (03) 136-141